On September 29, Gelonghui reported that Pacific Shuanglin Bio-pharmacy (000403.SZ) conducted an investor survey on September 26, 2024 regarding the "company's capacity expansion plan". The company stated that due to the continuous growth in plasma collection volume in recent years, the current capacity is insufficient to meet operational development needs. Both of the company's subsidiaries are expanding their capacities. The Phase II expansion of Guangdong Shuanglin is expected to be put into operation in the second half of 2025, with an annual capacity increase to 1500 tons; Pacific Sifei will also expand its capacity to an annual production capacity of 1500 tons in early 2025. The company's total annual capacity will reach 3000 tons to meet the future operational development needs.
派林生物(000403.SZ)：广东双林二期扩能预计2025年下半年投产，年产能将提升至1500吨
Pacific Shuanglin Bio-Pharmacy (000403.SZ): Guangdong Shuanglin Phase II expansion is expected to start production in the second half of 2025, with annual production capacity increasing to 1,500 tons.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated